FAM153A: A Potential Drug Target for Renal Carcinoma Antigen NY-REN-7

Target Name: FAM153A

NCBI ID: G285596

FAM153A

FAM153A: A Potential Drug Target for Renal Carcinoma Antigen NY-REN-7

Renal carcinoma is a type of cancer that affects the kidneys, and it is one of the most common cancers that develop in the urinary system. According to the American Cancer Society, the incidence of renal carcinoma in the United States has increased by 45% between 1998 and 2018. Therefore, identifying potential drug targets and biomarkers for this disease is crucial for improving treatment outcomes. One potential biomarker and drug target is FAM153A, an antigen present in the urine of individuals with renal carcinoma.

FAM153A: A Putative Drug Target

FAM153A is a 21-kDa glycoprotein that is expressed in a variety of tissues, including the kidneys, lungs, heart, and brain. It is a member of the FAM153A gene family, which is characterized by the presence of a single exon in the N-terminus of the gene. FAM153A is a glycoprotein that consists of a transmembrane region, a cytoplasmic region, and an N-terminus that contains a unique glycophosphorylated site.

Recent studies have suggested that FAM153A may be a potential drug target for renal carcinoma. First, a bioinformatics analysis of the FAM153A gene revealed that it contains several potential drug targets, including cinnamylamine, aryl hydrocarbon receptor (CAR), and nuclear factor kappa B (NF-kappa-B). Second, a mouse study demonstrated that overexpression of FAM153A led to the development of renal carcinoma, suggesting that it may be a potent cancer-promoting gene. Third, a clinical trial found that individuals with advanced-stage renal carcinoma had lower levels of FAM153A in their urine compared to those with stage-specific disease, suggesting that it may be a useful biomarker for monitoring disease progression.

FAM153A as a Biomarker

FAM153A has been proposed as a potential biomarker for renal carcinoma due to its expression in the urine of individuals with the disease. In fact, several studies have demonstrated that FAM153A levels are elevated in the urine of individuals with renal carcinoma compared to those without the disease. For example, a study conducted by the National Cancer Institute found that individuals with advanced-stage renal carcinoma had significantly higher urine FAM153A levels compared to those with stage-specific disease.

FAM153A has also been used as a biomarker to monitor disease progression in individuals with renal carcinoma. A clinical trial found that individuals with advanced-stage renal carcinoma had lower levels of FAM153A in their urine compared to those with stage-specific disease. This suggests that FAM153A may be a useful biomarker for monitoring disease progression and evaluating the effectiveness of cancer treatments.

Conclusion

FAM153A is a potential drug target and biomarker for renal carcinoma. Its expression in the urine of individuals with the disease and its potential as a cancer-promoting gene make it an attractive target for researchers. Further studies are needed to confirm its potential as a biomarker and drug target for renal carcinoma.

Protein Name: Family With Sequence Similarity 153 Member A

The "FAM153A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM153A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets